The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Marathon Pharmaceuticals
former U.S. rare disease drug company
Nothing else this week.
-
Biogen
American multinational biotechnology company
Nothing else this week.
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.